Search
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults.
Categories: Antigens, Differentiation, B-Lymphocyte, Genetically-modified Autologous T CellsSynonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell EngagerSynonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMARespiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil.
Categories: Botulinum Toxins, Type AButenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamineProducts: BUTEFIN %1 KREM, 15 G, BUTEFIN %1 KREM, 30 GAvobenzone
go.drugbank.com/drugs/DB09495ApprovedInvestigationalIt is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … Avobenzone is very sensitive to light, to increase its stability and duration of action, photostablizers are added in the sunscreen product. Avobenzone has an absorption maximum of 357 nm.
Mixtures: Derma-E Sensitive 3-in-1 sunscreen SPF 30, Hope In A Jar SPF 25Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesLisinopril
go.drugbank.com/drugs/DB00722ApprovedInvestigational[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. … Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.
Mixtures: LISINOPRIL E IDROCLOROTIAZIDE GIT, LISINOPRIL E IDROCLOROTIAZIDE GITCategories: Compounds used in a research, industrial, or household setting, Agents Acting on the Renin-Angiotensin SystemNuclear receptor subfamily 4 group A member 3
go.drugbank.com/bio_entities/BE0008998TargetHumansTranscriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. … Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity).
Synonyms: Translocated in extraskeletal chondrosarcomaSerine/threonine-protein kinase Nek4
go.drugbank.com/bio_entities/BE0009498TargetHumansRequired for normal cell cycle arrest in response to double-stranded DNA damage
Synonyms: Never in mitosis A-related kinase 4Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: BALVERSA 3 MG FİLM KAPLI TABLET, 56 ADET, BALVERSA 3 MG FİLM KAPLI TABLET, 84 ADET